Axonics receives regulatory approval for recharge-free snm system in australia

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) today announced that it has received regulatory approval from the therapeutic goods administration (tga) for marketing the axonics f15™ recharge-free sacral neuromodulation (snm) system in australia to treat adults with overactive bladder. “approval of the axonics recharge-free system is welcome news for australians with bladder and bowel dysfunction,” said dr. ailsa wilson edwards, a urologist at calvary north adelaide hospital. “i.
AXNX Ratings Summary
AXNX Quant Ranking